Could a common circulation drug stop strokes before they strike again?

NCT ID NCT07174414

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study tests whether adding cilostazol, a drug that improves blood flow, to standard aspirin or clopidogrel therapy can prevent another stroke or heart attack in people who have recently had a stroke or mini-stroke. About 2,000 participants will take either cilostazol or a placebo twice daily for several years. The goal is to see if the combination reduces major cardiovascular events like stroke, heart attack, or vascular death.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Cilostazol
What this could lead to
If it works, this could provide a new, affordable way to reduce the risk of another stroke or heart attack in people who have already had one.
What could go wrong
This is a large phase 3 trial, but cilostazol may not reduce events more than placebo, and it carries risks like bleeding or heart-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.